Monitor enrollment progress and any interim updates ahead of topline data in 2H 2027. This catalyst could drive significant value if results confirm efficacy and safety advantages over existing antipsychotics.
Price Chart
Executive Summary
LB Pharmaceuticals announced the initiation of its pivotal Phase 3 NOVA-2 trial evaluating LB-102, a novel benzamide antipsychotic, for the treatment of schizophrenia. The trial will enroll approximately 460 patients, with topline data expected in the second half of 2027. The company believes positive results could support a future NDA submission.
Key Facts
- LB Pharmaceuticals has initiated the Phase 3 NOVA-2 trial for LB-102 in schizophrenia.
- Trial is randomized, double-blind, placebo-controlled, enrolling ~460 patients across ~25 U.S. sites.
- Primary endpoint: change in PANSS total score at Week 6; secondary endpoints include negative symptoms, cognitive performance, and safety.
- Topline data expected in 2H 2027; if positive, company plans a pre-NDA meeting with the FDA.
- LB-102 is a selective D2/D3/5HT-7 antagonist and a methylated derivative of amisulpride, not approved in the U.S.
Financial Impact
No immediate financial impact disclosed; potential long-term commercial upside if approved.
Risk Factors
- Clinical trial delays or failure to meet endpoints in NOVA-2 could negatively impact valuation.
- LB-102 may face competition from established and emerging antipsychotics.
- Company has limited operating history and will likely require additional funding before commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.42 (+13.29%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.42 (−15.05%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $39.42 (−8.42%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.42 (−17.06%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $39.42 (−13.05%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $39.42 (−13.05%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.42 (+1.06%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.42 (+9.97%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.42 (+9.97%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.42 (+38.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers